8-KItem 7.01 · Reg FD DisclosureItem 8.01 · Other EventsItem 9.01 · Financial Statements
FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will…
Filed with the SEC on · Summarized by InvestorsBot
FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will not initiate review. Notice dated Feb 3, 2026; disclosed in Moderna 8-K (Item 8.01). $MRNA 🚫🧪 #FDA #BLA
Key facts — Product: mRNA-1010 (influenza). Agency: FDA CBER. Action: Refusal-to-File (review not initiated). Notice date Feb 3, 2026; 8-K filed Feb 11, 2026. $MRNA 🧾⚠️ #Moderna #influenza
Investors should watch for Moderna updates on FDA feedback, identified deficiencies and any resubmission timetable — these will determine next steps for U.S. approval prospects. $MRNA 📄🔁 #vaccine #BLA